Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
NEW YORK, Feb. 13, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Innocoll Holdings plc (“Innocoll”) (NASDAQ:INNL) between November 3, 2016 through December 29, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/innocoll-holdings-plc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Innocoll’s New Drug Application (“NDA”) submission to the FDA in October 2016 for XARACOLL was incomplete; (2) due to the incomplete NDA submission, XARACOLL would not be approved in 2017 as investors were led to believe; and (3) as a result, Defendants’ statements about Innocoll’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Innocoll you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
